Stephen Ross & Gabby Agin Liebes: Psilocybin for Cancer Related Anxiety & Depression - NYU Trial

Researchers at NYU detail the methodology and outcomes of their randomized controlled trial investigating psilocybin-assisted psychotherapy for cancer-related anxiety and depression. The study demonstrates that psilocybin acts as a rapid and sustained anxiolytic and antidepressant, with beneficial effects often persisting for over six months. Participants reported that these experiences fostered a positive phenomenological shift, characterized by a move from an initial sense of psychological fragmentation to a newfound state of interconnectedness. This 'ego-lysis' process allows individuals to disengage from defensive psychological structures and reframe their relationship with trauma and death.